U.S. flag

An official website of the United States government

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 3958

1.
Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria
Cochrane Database Syst Rev. 2021; 2021(1): CD004529. Published online 2021 Jan 18. doi: 10.1002/14651858.CD004529.pub3
PMCID:
PMC8094970
AbstractArticlePDF–1.1M
2.
Inhibitory role of proguanil on the growth of bladder cancer via enhancing EGFR degradation and inhibiting its downstream signaling pathway to induce autophagy
Di Xiao, Xin Hu, Mei Peng, Jun Deng, Sichun Zhou, Simeng Xu, Jingtao Wu, Xiaoping Yang
Cell Death Dis. 2022 May; 13(5): 499. Published online 2022 May 25. doi: 10.1038/s41419-022-04937-z
PMCID:
PMC9132982
AbstractArticlePDF–6.3M
3.
Mefloquine for preventing malaria during travel to endemic areas
Maya Tickell‐Painter, Nicola Maayan, Rachel Saunders, Cheryl Pace, David Sinclair, Cochrane Infectious Diseases Group
Cochrane Database Syst Rev. 2017 Oct; 2017(10): CD006491. Published online 2017 Oct 30. doi: 10.1002/14651858.CD006491.pub4
PMCID:
PMC5686653
AbstractArticlePDF–2.8M
4.
Cyclization-blocked proguanil as a strategy to improve the antimalarial activity of atovaquone
Tina S. Skinner-Adams, Gillian M. Fisher, Andrew G. Riches, Oliver E. Hutt, Karen E. Jarvis, Tony Wilson, Mark von Itzstein, Pradeep Chopra, Yevgeniya Antonova-Koch, Stephan Meister, Elizabeth A. Winzeler, Mary Clarke, David A. Fidock, Jeremy N. Burrows, John H. Ryan, Katherine T. Andrews
Commun Biol. 2019; 2: 166. Published online 2019 May 3. doi: 10.1038/s42003-019-0397-3
PMCID:
PMC6499835
AbstractArticlePDF–1.1M
5.
Prolonged malaria prophylaxis with chloroquine and proguanil (chloroguanide) in a nonimmune resident population of an endemic area with a high prevalence of chloroquine resistance.
D Gozal, C Hengy, G Fadat
Antimicrob Agents Chemother. 1991 Feb; 35(2): 373–376. doi: 10.1128/aac.35.2.373
PMCID:
PMC245009
SummaryPage BrowsePDF–762K
6.
Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers
Ryohkan Funakoshi, Yukana Tomoda, Toshiyuki Kudo, Kenichi Furihata, Hiroyuki Kusuhara, Kiyomi Ito
Br J Clin Pharmacol. 2019 Jul; 85(7): 1454–1463. Published online 2019 Apr 16. doi: 10.1111/bcp.13914
PMCID:
PMC6595331
AbstractArticlePDF–1.4M
7.
Proguanil and atovaquone use is associated with lower colorectal cancer risk: a nationwide cohort study
Naiqi Zhang, Jan Sundquist, Kristina Sundquist, Jianguang Ji
BMC Med. 2022; 20: 439. Published online 2022 Nov 10. doi: 10.1186/s12916-022-02643-3
PMCID:
PMC9650910
AbstractArticlePDF–919K
8.
Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population
Janelle M Hoskins, Gillian M Shenfield, Annette S Gross
Br J Clin Pharmacol. 1998 Nov; 46(5): 499–504. doi: 10.1046/j.1365-2125.1998.00807.x
Correction in:
Br J Clin Pharmacol, volume 47 on page 603
PMCID:
PMC1873690
AbstractArticlePDF–117K
9.
Clinical implications of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis
Henry M Staines, Rebekah Burrow, Beatrix Huei-Yi Teo, Irina Chis Ster, Peter G Kremsner, Sanjeev Krishna
J Antimicrob Chemother. 2018 Mar; 73(3): 581–595. Published online 2017 Dec 11. doi: 10.1093/jac/dkx431
PMCID:
PMC5890752
AbstractArticlePDF–691K
10.
Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis
Yan Wu, Tianyu Wu, Xin Hu, Simeng Xu, Di Xiao, Jingtao Wu, Xinjian Yan, Xiaoping Yang, Gaofeng Li
Int J Med Sci. 2022; 19(2): 233–241. Published online 2022 Jan 1. doi: 10.7150/ijms.67027
PMCID:
PMC8795793
AbstractArticlePDF–2.0M
11.
A Mechanism for the Synergistic Antimalarial Action of Atovaquone and Proguanil
Indresh K. Srivastava, Akhil B. Vaidya
Antimicrob Agents Chemother. 1999 Jun; 43(6): 1334–1339. doi: 10.1128/aac.43.6.1334
PMCID:
PMC89274
AbstractArticlePDF–110K
12.
In vitro atovaquone/proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand
Rommanee Khositnithikul, Peerapan Tan-ariya, Mathirut Mungthin
Malar J. 2008; 7: 23. Published online 2008 Jan 28. doi: 10.1186/1475-2875-7-23
PMCID:
PMC2265725
AbstractArticlePDF–258K
13.
Novel Endochin-Like Quinolones Exhibit Potent In Vitro Activity against Plasmodium knowlesi but Do Not Synergize with Proguanil
Donelly A. van Schalkwyk, Michael K. Riscoe, Sovitj Pou, Rolf W. Winter, Aaron Nilsen, Maëlle Duffey, Robert W. Moon, Colin J. Sutherland
Antimicrob Agents Chemother. 2020 May; 64(5): e02549-19. Prepublished online 2020 Feb 24. Published online 2020 Apr 21. doi: 10.1128/AAC.02549-19
PMCID:
PMC7179610
AbstractArticlePDF–987K
14.
Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population
Lise Bathum, Erik Skjelbo, Theonest K Mutabingwa, Hanne Madsen, Mogens Hørder, Kim Brøsen
Br J Clin Pharmacol. 1999 Sep; 48(3): 395–401. doi: 10.1046/j.1365-2125.1999.00019.x
PMCID:
PMC2014329
AbstractArticlePDF–114K
15.
Synthesis, Anti-Proliferative Evaluation and Mechanism of 4-Trifluoro Methoxy Proguanil Derivatives with Various Carbon Chain Length
Simeng Xu, Yufang Cao, Yu Luo, Di Xiao, Wei Wang, Zhiren Wang, Xiaoping Yang
Molecules. 2021 Oct; 26(19): 5775. Published online 2021 Sep 24. doi: 10.3390/molecules26195775
PMCID:
PMC8510509
AbstractArticlePDF–2.4M
16.
Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man.
S A Ward, W M Watkins, E Mberu, J E Saunders, D K Koech, H M Gilles, R E Howells, A M Breckenridge
Br J Clin Pharmacol. 1989 Jun; 27(6): 781–787. doi: 10.1111/j.1365-2125.1989.tb03440.x
PMCID:
PMC1379805
SummaryPage BrowsePDF–848K
17.
Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects.
Y Wattanagoon, R B Taylor, R R Moody, N A Ochekpe, S Looareesuwan, N J White
Br J Clin Pharmacol. 1987 Dec; 24(6): 775–780. doi: 10.1111/j.1365-2125.1987.tb03245.x
PMCID:
PMC1386403
SummaryPage BrowsePDF–748K
18.
In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.
D J Birkett, D Rees, T Andersson, F J Gonzalez, J O Miners, M E Veronese
Br J Clin Pharmacol. 1994 May; 37(5): 413–420. doi: 10.1111/j.1365-2125.1994.tb05707.x
PMCID:
PMC1364895
SummaryPage BrowsePDF–1.2M
19.
Pancytopenia due to proguanil toxicity in a returning traveller with fever
Hetty Jolink, Jan den Hartigh, Leo G. Visser, Cees van Nieuwkoop
Eur J Clin Pharmacol. 2010; 66(8): 811–812. Published online 2010 Apr 21. doi: 10.1007/s00228-010-0824-3
PMCID:
PMC2904905
AbstractArticlePDF–77K
20.
Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.
K Brøsen, E Skjelbo, H Flachs
Br J Clin Pharmacol. 1993 Aug; 36(2): 105–108. doi: 10.1111/j.1365-2125.1993.tb04204.x
PMCID:
PMC1364572
SummaryPage BrowsePDF–707K

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Search details

See more...

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center